Rituximab je základem léčby Castlemanovy nemoci – multicentrického typu
| Title in English | Rituximab represents the standard component in the treatment of the multicentric type of Castleman disease |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Postgraduální medicína |
| MU Faculty or unit | |
| Citation | |
| Field | Oncology and hematology |
| Keywords | Castleman disease • rituximab |
| Description | Castleman disease is non-malignant disorder mimicking in its multicentric form malignant lymphoma or multiple myeloma. While unicentric form is usually successfully treated with surgery multicentric form necessitates immunotherapy with rituximab supplemented with chemotherapy when needed. The aim of this short communication is to draw the attention to this relatively rare clinical unit that may represent a diagnostic challenge. |